Adam Sperling, MD, PhD

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.

Adam Sperling, MD, PhD, from the Dana-Farber Cancer Institute, and an instructor in medicine at Harvard Medical School, discussed managing CAR T-cell therapy–related toxicities in multiple myeloma.

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future directions that ide-cel research may take.